Link copied to clipboard!

Wockhardt Hospital, SOBO launches “Diabetes Clinic”

IMT News Desk
IMT News Desk
· 3 min read

Bangalore, November 22, 2018:   With a growing number of diabetic patients in the country, there is a dire need for more clinics so that affected people are saved from Diabetes & Diabetes related problems. Wockhardt Hospital, Mumbai Central a JCI & NABH Accredited hospitals in association with Wellthy Therapeutics a South Asia’s leading Digital Therapeutic Company has launched a “Diabetes Clinic”. Digital technologies suite for diabetes will be used to help people in treatment from the medical condition. The Launch had been followed by seminar for visiting patients with free check up of HbA1c test and diabetes camp.

Digital therapeutics, also known as “software as a drug,” involves the use of digital tools or systems to treat medical conditions. In digital therapeutics, digital technologies such as apps, devices and software are used to treat patients in the same way drugs, surgeries or medical devices are applied therapeutically. Digital therapeutics may be used as stand-alone treatments or as part of a broader treatment program that incorporates both digital and non-digital (conventional) therapies.

Diabetes is a growing challenge in India with estimated 8.7% diabetic population in the age group of 20 and 70 years. The rising prevalence of diabetes and other non-communicable diseases is driven by a combination of factors – rapid urbanization, sedentary lifestyles, unhealthy diets, tobacco use, and increasing life expectancy. India currently represents 49 percent of the world’s diabetes burden, with an estimated 72 million cases in 2017, a figure expected to almost double to 134 million by 2025. Diabetes prevalence has increased by 64 percent across India over the quarter-century, according to a November 2017 report by the Indian Council for Medical Research, Institute for Health Metrics and Evaluation, both research institutes, and the Public Health Foundation of India, an advocacy.

 Dr. Parag Rindani, Centre Head at Wockhardt Hospital, SOBO says, “Newly launched Diabetes clinic will be dedicated to provide accessible medical treatment for patients who seek aid with various problems related to diabetes. Our patients with chronic conditions like diabetes stand to benefit from continuous and real-time care provided by Wellthy Therapeutics’ digital therapeutic suite, as we enable out-of-clinic extensions to our world-class in-clinic care to help our patients improve their health outcomes. Diabetes clinic will comprise of endocrinologist, Diabetic Foot Surgeon, Neurologist, internal medicine expert and other specialties.”

Dr Behram Pardiwala, Internal Medicine Expert, Wockhardt Hospital, SOBO says, “Lifestyle modification is the most important component of diabetes care. Patients who follow healthy diets, exercise regularly is better positioned to prevent other complications that result from mismanagement of diabetes.

“Our out-of-clinic clinically-validated digital therapeutic perfectly complements the state-of-the-art in-clinic care for patients with diabetes at Wockhardt Hospitals. We strongly believe that the combination will enable better patient outcomes and a better quality of life. We are excited to launch this partnership to augment care for all Wockhardt patients and stakeholders.” said Abhishek Shah, co-founder and CEO, Wellthy Therapeutics.

Read Next

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management
Corporate
January 27, 2026

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management

Company to launch product after the expiry of semaglutide patent in India Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to […]
Article by: IMT News Desk
Lupin receives highest ESG rating from CDP for climate change and water security
Corporate
January 27, 2026

Lupin receives highest ESG rating from CDP for climate change and water security

The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency at the highest level Lupin has received the highest ‘A’ leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency […]
Article by: IMT News Desk
AstraZeneca Pharma India receives CDSCO approval for breast cancer drug
Corporate
December 19, 2025

AstraZeneca Pharma India receives CDSCO approval for breast cancer drug

Dato-DXd is a specifically engineered antibody drug conjugate that targets TROP2, a protein frequently overexpressed in breast cancer AstraZeneca Pharma India announced that the Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to import, sell, and distribute Datopotamab Deruxtecan (Dato-DXd) in India. The approval reflects AstraZeneca’s focus on bringing to life-changing medicines at […]
Article by: IMT News Desk
Novo Nordisk launches Ozempic in India
Corporate
December 12, 2025

Novo Nordisk launches Ozempic in India

Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus Novo Nordisk announced the launch of Ozempic (injectable semaglutide) in India. Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living […]
Article by: IMT News Desk